Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling

Blood

Volumn 93, Issue 12, 1999, Pages 4354-4364

  Ho, Jen M Y ^b   Seattle, Bryan K ^b   Squire, Jeremy A ^b   Frank, David A ^b   Barber, Dwayne L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; HYBRID PROTEIN; INTERLEUKIN 3; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; HEMATOPOIETIC CELL; LEUKEMOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 0344517071     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.12.4354     Document Type: Article

References (65)

1. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KC, Yin L, Pennica D, Johnson EM Jr, Schreiber RD: Disruption of the Jak 1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93:373, 1998
2. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, Grosveld G, Ihle JN: Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93:385, 1998
3. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K: Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93:397, 1998
4. Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, Doherty PC, Grosveld GC, Ihle JN: Defective lymphoid development in mice lacking Jak3. Science 270:800, 1995
5. Park SY, Saijo K, Takahashi T, Osawa M, Arase H, Hirayama N, Miyake K, Nakauchi H, Shirasawa T, Saito T: Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3:771, 1995
6. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ: Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270:794, 1995
7. Saijo K, Park SY, Ishida Y, Arase H, Saito T: Crucial role of Jak3 in negative selection of self-reactive T cells. J Exp Med 185:351, 1997
8. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S: Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 94:3801, 1997
9. Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN: Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382:171, 1996
10. Kaplan MH, Sun YL, Hoey T, Grusby MJ: Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382:174, 1996
11. Teglund S, McKay C, Schuetz E, Deursen JMV, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN: Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93:841, 1998
12. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle FW, Nosaka T, Vignali DA, Doherty PC, Grosveld G, Paul WE, Ihle JN: Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380:630, 1996
13. Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse JF, Capiod JC, Delobel J, Weber-Nordt R, Dusanter-Foun I, Dreyfus F, Groner B, Prin L: STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87:1692, 1996
14. Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R, Finke J: Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88:809, 1996
15. van der Plas DC, Smiers F, Pouwels K, Hoefsloot LH, Lowenberg B, Touw IP: Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain. Leukemia 10:1317, 1996
16. Luo H, Rose P, Barber D, Hanratty WP, Lee S, Roberts TM, D'Andrea AD, Dearolf CR: Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol 17:1562, 1997
17. Gotoh A, Broxmeyer HE: The function of BCR/ABL and related proto-oncogenes. Curr Opin Hematol 4:3, 1997
18. Janssen JW, Ridge SA, Papadopoulos P, Cotter F, Ludwig WD, Fonatsch C, Rieder H, Ostertag W, Bartram CR, Wiedemann LM: The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event. Br J Haematol 90:222, 1995
19. Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, Bohlander SK, Rowley JD, Witte ON, Gilliland DG: Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 16:4107, 1996
20. Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307, 1994
21. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P: Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90:2535, 1997
22. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA: A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309, 1997
23. Zhuang H, Patel SV, He TC, Sonsteby SK, Niu Z, Wojchowski DM: Inhibition of erythropoietin-induced mitogenesis by a kinase-deficient form of Jak2. J Biol Chem 269:21411, 1994
24. Barber DL, D'Andrea AD: Erythropoietin and interleukin-2 activate distinct JAK kinase family members. Mol Cell Biol 14:6506, 1994
25. Frank DA, Robertson M, Bonni A, Ritz J, Greenberg ME: IL-2 signaling onvolves the phosphorylation of novel Stat proteins. Proc Natl Acad Sci USA 92:7779, 1995
26. Bonni A, Sun Y, Nadal-Vicens M, Bhatt A, Frank DA, Rozovsky I, Stahl N, Yancopoulos GD, Greenberg ME: Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science 278:477, 1997
27. Gollob JA, Murhy EA, Mahajan S, Schnipper CP, Ritz J, Frank DA: Altered IL-12 responsiveness in Th1 and Th2 cells is associated with the differential activation of STAT5 and STAT1. Blood 91:1341, 1998
28. Wakao H, Gouilleux F, Groner B: Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J 13:2182, 1994
29. Pine R, Canova A, Schindler C: Tyrosine phosphorylated p91 binds to a single element in the ISGF2/IRF-1 promoter to mediate induction by IFN alpha and IFN gamma, and is likely to autoregulate the p91 gene. EMBO J 13:158, 1994
30. Jaster R, Zhu Y, Pless M, Bhattacharya S, Mathey-Prevot B, D'Andrea AD: JAK2 is required for induction of the murine DUB-1 gene. Mol Cell Biol 17:3364, 1997
31. Klambt C: The Drosophila gene pointed encodes two ETS-like proteins which are involved in the development of the midline glial cells. Development 117:163, 1993
32. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG: The TEL/platelet-derived growth factor β-receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways. Proc Natl Acad Sci USA 93:14845, 1996
33. Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, Liu ET, Ihle JN: Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 370:153, 1994
34. Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse J-F, Capoid J-C, Delobel J, Weber-Nordt R, Dusanter-Fourt I, Dreyfus F, Groner B, Prin L: STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87:1692, 1996
35. Wakao H, Harada N, Kitamura T, Mui AL, Miyajima A: Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways. EMBO J 14:2527, 1995
36. Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya K, Ortaldo JR, Gupta S, Chen YQ, Gin JD, O'Shea JJ: Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci USA 92:8705, 1995
37. Azam M, Erdjument-Bromage H, Kreider BL, Xia M, Quelle F, Basu R, Saris C, Tempst P, Ihle JN, Schindler C: Interleukin-3 signals through multiple isoforms of Stat5. EMBO J 14:1402, 1995
38. Mui AL, Wakao H, O'Farrell AM, Harada N, Miyajima A: Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J 14:1166, 1995
39. Gouilleux F, Pallard C, Dusanter-Fourt I, Wakao H, Haldosen LA, Norstedt G, Levy D, Groner B: Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. EMBO J 14:2005, 1995
40. Damen JE, Wakao H, Miyajima A, Krosl J, Humphries RK, Cutler RL, Krystal G: Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. EMBO J 14:5557, 1995
41. Klingmuller U, Bergelson S, Hsiao JG, Lodish HF: Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5. Proc Natl Acad Sci USA 93:8324, 1996
42. Quelle FW, Wang D, Nosaka T, Thierfelder WE, Stravopodis D, Weinstein Y, Ihle JN: Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response. Mol Cell Biol 16:1622, 1996
43. Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I, Charon M, Levin J, Bernard O, Ghysdael J: A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFRβ oncoprotein. EMBO J 16:69, 1997
44. Sato Y, Iijima Y, Ito T, Oikawa T, Eguchi M, Eguchi-Ishimae M, Kamada N, Kishi K, Asano S, Sakaki Y: A new partner gene of the ETV6/TEL, ARG (Abl related gene, or ABL2) cloned in a AML-M3 cell line with t(1;12)(q25;p13). Blood 93:592a, 1998 (abstr, suppl 1)
45. Knezevich SR, McFadden DE, Tao W, Lira JF, Sorensen PH: A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 18:184, 1998
46. Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sato Y, Kudoh S, Tanaka K, Setoyama M, Nagamura F, Asano S, Kamada N: Fusion of ETV6 to neutrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 93:1355, 1999
47. Tse KF, Civin C, Small D: Constitutive activation of STK-1 tyrosine kinase by HLH domain of transcription factor TEL. Blood 90:311a, 1997 (abstr, suppl 1)
48. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, Peeters P, Rompaey LV, Etten RAV, Ilaria R, Marynen P, Gilliland DG: Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative syndrome in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 17:5321, 1998
49. Shikama Y, Barber DL, D'Andrea AD, Sieff CA: A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines. Blood 88:455, 1996
50. Silvennoinen O, Witthuhn BA, Quelle FW, Cleveland JL, Yi T, Ihle JN: Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction, Proc Natl Acad Sci USA 90:8429, 1993
51. DaSilva L, Rui H, Erwin RA, Howard OM, Kirken RA, Malabarba MG, Hackett RH, Larner AC, Farrar WL: Prolactin recruits STAT1, STAT3 and STAT5 independent of conserved receptor tyrosines TYR402, TYR479, TYR515 and TYR580. Mol Cell Endocrinol 117:131, 1996
52. Ascherman DP, Migone TS, Friedmann MC, Leonard WJ: Interleukin-2 (IL-2)-mediated induction of the IL-2 receptor alpha chain gene. Critical role of two functionally redundant tyrosine residues in the IL-2 receptor beta chain cytoplasmic domain and suggestion that these residues mediate more than Stat5 activation. J Biol Chem 272:8704, 1997
53. Itoh T, Liu R, Yokota T, Arai KI, Watanabe S: Definition of the role of tyrosine residues of the common beta subunit regulating multiple signaling pathways of granulocyte-macrophage colony-stimulating factor receptor. Mol Cell Biol 18:742, 1998
54. Hemmann U, Gerhartz C, Heesel B, Sasse J, Kurapkat G, Grotzinger J, Wollmer A, Zhong Z, Darnell JE Jr, Graeve L, Heinrich PC, Horn F: Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J Biol Chem 271:12999, 1996
55. Stahl N, Farruggella TJ, Boulton TG, Zhong Z, Darnell JE Jr, Yancopoulos GD: Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267:1349, 1995
56. Gerhartz C, Heesel B, Sasse J, Hemmann U, Landgraf C, Schneider-Mergener J, Horn F, Heinrich PC, Graeve L: Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J Biol Chem 271:12991, 1996
57. Carlesso N, Frank DA, Griffin JD: Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 183:811, 1996
58. Shuai K, Halpern J, Hoeve JT, Rao X, Sawyers CL: Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13:247, 1996
59. Frank DA, Varticovski L: BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 10:1724, 1996
60. Chai SK, Nichols GL, Rothman P: Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 159:4720, 1997
61. Klucher KM, Lopez DV, Daley GQ: Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood 91:3927, 1998
62. Onishi M, Nosaka T, Misawa K, Mui AL-F, Gorman D, McMahon M, Miyajima A, Kitamura T: Identification and characterization fo a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol 18:3871, 1998
63. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG: Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 92:4917, 1995
64. Golub TR, McLean T, Stegmaier K, Carroll M, Tomasson M, Gilliland DG: The TEL gene and human leukemia. Biochim Biophys Acta 1288:M7, 1996
65. Peeters P, Wlodarska I, Baens M, Criel A, Selleslag D, Hagemeijer A, Van den Berghe H, Marynen P: Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res 57:564, 1997